Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from PharmaTher Holdings Ltd ( (TSE:PHRM) ) is now available.
PharmaTher Holdings Ltd. announced that the FDA has extended the review period for its new drug application for ketamine, with a new approval goal date set for August 9, 2025. The extension is due to a minor amendment and is not expected to significantly impact the company’s ongoing operations or business initiatives for 2025.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on the research and commercialization of KETARX™ (Ketamine) to address unmet medical needs in surgery, pain, mental health, neurological, and medical countermeasures indications.
Average Trading Volume: 42,102
Technical Sentiment Signal: Buy
Current Market Cap: C$20.36M
See more insights into PHRM stock on TipRanks’ Stock Analysis page.